Paralysis – Pipeline Review, H2 2012

Paralysis – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Paralysis - Pipeline Review, H2 2012', provides an overview of the Paralysis therapeutic pipeline. This report provides information on the therapeutic development for Paralysis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Paralysis. 'Paralysis - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Paralysis.
- A review of the Paralysis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Paralysis pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Paralysis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Paralysis pipeline depth and focus of Paralysis therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Paralysis Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Paralysis 7
Paralysis Therapeutics under Development by Companies 9
Paralysis Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 12
Comparative Analysis 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Early Clinical Stage Products 14
Comparative Analysis 14
Pre-Clinical Stage Products 15
Comparative Analysis 15
Paralysis Therapeutics – Products under Development by Companies 16
Paralysis Therapeutics – Products under Investigation by Universities/Institutes 17
Companies Involved in Paralysis Therapeutics Development 18
Neuralstem, Inc. 18
Paralysis – Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Combination Products 20
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Drug Profiles 25
Sodium Oxybate - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Dichlorphenamide - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Humanized Mik-(Beta)-1 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
NSI-566RSC - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Pentoxifylline + Tocopherol Acetate + Clodronic Acid - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Tamibarotene - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
L-NAME + Midodrine Hydrochloride - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Paralysis Therapeutics – Drug Profile Updates 33
Paralysis Therapeutics - Dormant Products 35
Appendix 36
Methodology 36
Coverage 36
Secondary Research 36
Primary Research 36
Expert Panel Validation 36
Contact Us 37
Disclaimer 37

List of Tables
Number of Products Under Development for Paralysis, H2 2012 7
Products under Development for Paralysis – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 11
Comparative Analysis by Late Stage Development, H2 2012 12
Comparative Analysis by Mid Clinical Stage Development, H2 2012 13
Comparative Analysis by Early Clinical Stage Development, H2 2012 14
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 15
Products under Development by Companies, H2 2012 16
Products under Investigation by Universities/Institutes, H2 2012 17
Neuralstem, Inc., H2 2012 18
Assessment by Monotherapy Products, H2 2012 19
Assessment by Combination Products, H2 2012 20
Assessment by Stage and Route of Administration, H2 2012 22
Assessment by Stage and Molecule Type, H2 2012 24
Paralysis Therapeutics – Drug Profile Updates 33
Paralysis Therapeutics – Dormant Products 35

List of Figures
Number of Products under Development for Paralysis, H2 2012 7
Products under Development for Paralysis – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 12
Mid Clinical Stage Products, H2 2012 13
Early Clinical Stage Products, H2 2012 14
Pre-Clinical Stage Products, H2 2012 15
Assessment by Monotherapy Products, H2 2012 19
Assessment by Combination Products, H2 2012 20
Assessment by Route of Administration, H2 2012 21
Assessment by Stage and Route of Administration, H2 2012 22
Assessment by Molecule Type, H2 2012 23
Assessment by Stage and Molecule Type, H2 2012 24